Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma

NCT06068400 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Due to corporate strategic adjustment.

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: BCMA/GPRC5D dual CAR-T

Sponsor

Guangzhou Bio-gene Technology Co., Ltd

Collaborators

[object Object]